Nothing Special   »   [go: up one dir, main page]

Zanzonico et al., 2015 - Google Patents

PET-based compartmental modeling of 124 I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer

Zanzonico et al., 2015

Document ID
9802119779714415572
Author
Zanzonico P
Carrasquillo J
Pandit-Taskar N
O’Donoghue J
Humm J
Smith-Jones P
Ruan S
Divgi C
Scott A
Kemeny N
Fong Y
Wong D
Scheinberg D
Ritter G
Jungbluth A
Old L
Larson S
Publication year
Publication venue
European journal of nuclear medicine and molecular imaging

External Links

Snippet

Purpose The molecular specificity of monoclonal antibodies (mAbs) directed against tumor antigens has proven effective for targeted therapy of human cancers, as shown by a growing list of successful antibody-based drug products. We describe a novel, nonlinear …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate

Similar Documents

Publication Publication Date Title
Parakh et al. Radiolabeled antibodies for cancer imaging and therapy
Chomet et al. Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89 Zr-immuno-PET
Carrasquillo et al. 124I-huA33 antibody PET of colorectal cancer
Van Dongen et al. Immuno-PET: a navigator in monoclonal antibody development and applications
Mayer et al. A Phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti–carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug
ES2802234T3 (en) Systems and methods for determining the optimal and patient-specific dose of tumor-directed antibodies
Cheal et al. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex
Kraeber-Bodéré et al. Tumor immunotargeting using innovative radionuclides
Tolmachev et al. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels
Bourgeois et al. Radioimmunoconjugates for treating cancer: recent advances and current opportunities
O’Donoghue et al. Pharmacokinetics and biodistribution of a [89Zr] Zr-DFO-MSTP2109A anti-STEAP1 antibody in metastatic castration-resistant prostate cancer patients
Chan et al. A comparison of 111 In-or 64 Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT
Zanzonico et al. PET-based compartmental modeling of 124 I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer
Waaijer et al. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
Carrasquillo et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
Lindegren et al. Binding affinity, specificity and comparative biodistribution of the parental murine monoclonal antibody MX35 (Anti-NaPi2b) and its humanized version Rebmab200
Scott et al. First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers
Casey et al. Tumour targeting of humanised cross-linked divalent-Fab′ antibody fragments: a clinical phase I/II study
Jauw et al. Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
Ku et al. Dose predictions for [177 Lu] Lu-DOTA-panitumumab F (ab′) 2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64 Cu] Cu-DOTA-panitumumab F (ab′) 2–implications for a PET theranostic strategy
Bellaye et al. Radiolabeled F (ab′) 2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models
Kurdziel et al. First-in-human phase 0 study of 111In-CHX-A”-DTPA trastuzumab for HER2 tumor imaging
Foubert et al. Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: comparison with 18FDG PET-CT
Heo et al. Folate receptor α-targeted 89Zr-M9346A immuno-PET for image-guided intervention with mirvetuximab soravtansine in triple-negative breast cancer
Ghai et al. Development of [89 Zr] DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma